SG3 Management’s Clover Health Investments CLOV Stock Holding History

SG3 Management’s Portfolio CLOV Stock Details CLOV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-37,500	Closed	-$140K	–	1022
2021 Q4	$140K	Buy	+37,500	New	+$230K	﹤0.01%	863

Other funds holding CLOV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

SG3 Management's CLOV Position: Q1 2022 in Review

SG3 Management sold out of Clover Health Investments (CLOV) in Q1 2022, closing a stake of 37,500 shares — an estimated $140K sold.

SG3 Management first reported a position in CLOV in Q4 2021 and held it in 1 quarter. The position peaked at $140K in Q4 2021. 168 funds tracked by Wall St. Rank hold CLOV as of Q1 2022.

SG3 Management reported no remaining Clover Health Investments position as of Q1 2022 after selling out during the quarter.
SG3 Management sold 37,500 Clover Health Investments shares in Q1 2022, an estimated $140K.
SG3 Management first reported a position in Clover Health Investments in Q4 2021 and held it in 1 quarter.
SG3 Management's Clover Health Investments position peaked at $140K in Q4 2021.
168 funds tracked by Wall St. Rank held Clover Health Investments as of Q1 2022.

Based on SG3 Management's 13F filing for Q1 2022, filed 16 May 2022.